文献速递肾小球疾病慢性肾脏病

药物重定位用于足细胞功能障碍相关疾病

Repurposing drugs for diseases associated with podocyte dysfunction.
PubMed 文献 · Kidney Int · 2023-06-07

本文为综述,探讨将已获FDA、EMA等监管机构批准用于非肾脏适应症的药物重定位至足细胞病。足细胞病多呈进展性,可致慢性肾脏病甚至肾衰竭,现有治疗多为非特异性免疫抑制剂且副作用严重。文章检视足细胞损伤的实验文献,以确定可供重定位药物作用的机制靶点。

要点

  • 足细胞病多进展至慢性肾脏病和肾衰竭,现有治疗多为非特异性免疫抑制剂且副作用严重。
  • 药物重定位的优势包括安全性已知、药物开发已完成、研究替代适应症的成本总体降低。
  • 本文检视足细胞损伤的实验文献,以确定可供已批准药物重定位的机制靶点。

核心结论

  • 本文旨在检视足细胞损伤的实验文献,确定是否存在可供已批准药物重定位用于足细胞病的机制靶点。

研究设计与样本

  • 本文为小型综述,检视足细胞损伤的实验文献。
  • 综述范围涉及已获美国食品药品监督管理局、欧洲药品管理局及其他监管机构批准用于肾脏以外适应症的药物。

主要发现

  • 足细胞病多数呈进展性,可导致慢性肾脏病并常致肾衰竭。
  • 当前治疗范围通常为非特异性免疫抑制剂,伴有不良且严重的副作用。
  • 许多临床试验正在进行,以减轻足细胞病患者的疾病负担。
  • 实验研究在理解疾病中足细胞损伤的分子和细胞机制方面近期取得重大进展和发现。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The majority of podocyte disorders are progressive in nature leading to chronic kidney disease and often kidney failure. The scope of current therapies is typically nonspecific immunosuppressant medications, which are accompanied by unwanted and serious side effects. However, many exciting clinical trials are underway to reduce the burden of podocyte diseases in our patients. Major advances and discoveries have recently been made experimentally in our understanding of the molecular and cellular mechanisms underlying podocyte injury in disease. This begs the question of how best to take advantage of these impressive strides. One approach to consider is the repurposing of therapeutics that have already been approved by the Food and Drug Administration, European Medicines Agency, and other regulatory agencies for indications beyond the kidney. The advantages of therapy repurposing include known safety profiles, drug development that has already been completed, and overall reduced costs for studying alternative indications for selected therapies. The purpose of this mini review is to examine the experimental literature of podocyte damage and determine if there are mechanistic targets in which prior approved therapies can be considered for repurposing to podocyte disorders.

来源:Kidney Int,查看原文。版权归原作者所有。

引用

  1. Shankland SJ, Jefferson JA, Wessely O, et al. Repurposing drugs for diseases associated with podocyte dysfunction. Kidney Int. 2023. PMID: 37290603. doi:10.1016/j.kint.2023.05.018

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。